Skip to Content


John J. Ferrante et al.; Proposal to Withdraw Approval of 158 Abbreviated New Drug Applications; Opportunity for a Hearing

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.




The Food and Drug Administration (FDA) is announcing an opportunity for a hearing on the agency's proposal to withdraw approval of 158 abbreviated new drug applications (ANDA's). The basis for the proposal is that the sponsors have repeatedly failed to file required annual reports for these applications.


Submit written requests for a hearing by April 27, 2000; submit data and information in support of the hearing request by May 30, 2000.


Requests for a hearing, supporting data, and other comments are to be identified with Docket No. 00N-1198 and submitted to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

Start Further Info


Olivia A. Pritzlaff, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.

End Further Info End Preamble Start Supplemental Information


The holders of approved applications to market new drugs for human use are required to submit annual reports to FDA concerning each of their approved applications in accordance with § 314.81 (21 CFR 314.81). The holders of the applications listed in the following table have failed to submit the required annual reports and have not responded to the agency's request by certified mail for submission of the reports.

ANDA No.DrugApplicant
60-058Chloramphenicol Capsules, 250 milligrams (mg).John J. Ferrante, c/o Operations Management Consulting, 11 Fairway Lane, Trumbull, CT 06611.
60-062Penicillin G Potassium.The Upjohn Co., 700 Portage Rd., Kalamazoo, MI 49001.
60-094Sterile Penicillin G Procaine Suspension USP.Do.
60-110Sterile Dihydrostreptomycin Sulfate USP.Pfizer Central Research, Pfizer, Inc., Eastern Point Rd., Groton, CT 06340.
60-170Penicillin G Potassium Tablets, 200,000, 250,000, and 400,000 units.John J. Ferrante.
60-173Tetracycline Hydrochloride (HCl) Capsules, 250 mg.Do.
60-174Tetracycline Oral Suspension, 125 mg/5 milliliters (mL).Do.
60-177Bacitracin-Neomycin Sulfate Polymyxin B Sulfate Ointment.Do.
60-178Bacitracin-Neomycin Sulfate Ointment.Do.
60-179Oxytetracycline HCl Capsules, 250 mg.Do.
60-188Neomycin Sulfate and Hydrocortisone Actetate Ophthalmic Suspension USP.Akorn, Inc., c/o Walnut Pharmaceuticals, Inc., 1340 North Jefferson St., Anaheim, CA 92807.
60-360Neomycin and Polymyxin B Sulfate and Bacitracin Ointment with Benzocaine.Ambix Laboratories, 210 Orchard St., East Rutherford, NJ 07073.
60-435Tetracycline HCl Tablets USP, 250 mg.Farmitalia Carlo Erba S.p.A., c/o Montedison, USA, Inc., 1114 Avenue of the Americas, New York, NY 10036.
60-453Neomycin and Polymyxin B Sulfate and Bacitracin Ointment with Diperodon HCl.Ambix Laboratories.
60-464Neomycin Sulfate and Prednisolone.The Upjohn Co.
60-647Neo-Polycin Opthalmic Ointment.Merrell Dow Pharmaceuticals, Inc., P.O. Box 68511, Indianapolis, IN 46268.
60-666Ampicillin Tihydrate for Oral Suspension.Beecham Laboratories, 501 Fifth St., Bristol, TN 37620.
60-690Oxytetracycline HCl.Pierrel America, Inc., 576 Fifth Ave., New York, NY 10036.
60-720Tetracycline HCl Capsules, 250 mg.Towne Paulsen & Co., Inc., 140 East Duarte Rd., Monrovia, CA 91016.
60-757Polymyxin B Sulfate, 500,000 units.Burroughs Wellcome Co., 3030 Cornwallis Rd., Research Triangle Park, NC 27709.
60-774Griseofulvin Tablets, 500 mg.McNeil Consumer, Inc., Camp Hill Rd., Fort Washington, PA 19034.
60-809Penicillin G Potassium Tablets USP, 100,000, 200,000, 250,000, 400,000, and 500,000 units.Consolidated Pharmaceutical Group, 6110 Robinwood Rd., Baltimore, MD 21225.
60-855Oxytetracycline HCl Capsules, 250 mg.Rachelle Laboratories, Inc., 700 Henry Ford Ave., P.O. Box 2029, Long Beach, CA 90801.
60-869Oxytetracycline HCl Capsule, 250 mg.Proter S.p.A., c/o Arnold Buhl Christen, 1000 Connecticut Ave., Washington, DC 20086.
61-174Candicidin.Penick Corp., 1050 Wall St. West, Lyndhurst, NJ 07071.
61-396Hetacillin Capsules.Bristol-Myers, U.S. Pharmaceutical Group, Evansville, IN 47721-0001.
61-523Tetracycline HCl Susceptibility Power, 20 mg.Lederle Laboratories, Division of American Cyanamid Co., Pearl River, NY 10965.
61-676Ampicillin Trihydrate Capsules, 250 mg and 500 mg.Public Health Service, Health Service Administration, Perry Point, MD 21902.
61-700Bacitracin Zinc USP for Compounding.Alpharma A.S., One Executive Dr., P.O. Box 1399, Fort Lee, NJ 07024.
61-718Nystatin Vaginal Tablets USP, 100,000 units.Holland-Rantos Co., Inc., 310 Enterprise Ave., Trenton, NJ 08638.
61-720Doxycycline Oral Suspension USP.Rachelle Laboratories, Inc.
Start Printed Page 16398
61-933Penicillin G Potassium for Injection USP.E.R. Squibb & Sons, P.O. Box 191, New Brunswick, NJ 08903-0191.
61-953Doxycycline Hyclate Injection.Rachelle Laboratories, Inc., P.O. Box 187, Culver, IN 46511.
61-957Benzylpenicilloyl Polylysine Injection.Kremers-Urban Co., 5600 West County Line Rd., P.O. Box 2038, Milwaukee, WI 53201.
61-961Bacitracin Ointment USP.Clay-Park Labs, Inc., 1700 Bathgate Ave., Bronx, NY 10457.
61-994Kanamycin Sulfate Injection USP.Bristol Laboratories, Division of Bristol-Myers Co., P.O. Box 657, Syracuse, NY 13201.
62-007Bacitracin USP, 50,000 and 10,000 units/vial.Alpharma A.S., c/o Alpharma, Inc., One Executive Dr., P.O. Box 1399, Fort Lee, NJ 07024.
62-042Chloramphenicol Ophthalmic Solution, 0.5%.Akorn, Inc.
62-138Cefoxitin Solution.Pfizer Pharmaceuticals, Inc., 235 East 42d St., New York, NY 10017.
62-224Neomycin Sulfate Ointment.Clay-Park Labs, Inc.
62-236Bacitracin Ointment USP.Denison Laboratories, Inc., 60 Dunnell Lane, P.O. Box 1305, Pawtucket, RI 02862.
62-248Gentamicin Sulfate Injection USP.The Upjohn Co.
62-345Tetracycline HCl Capsules, 250 mg.Public Health Service, HAS Supply Service Center, Perry Point, MD 21902.
62-354Gentamicin Sulfate Injection USP.Kalapharm, Inc., 145 East 27th St., New York, NY 10016.
62-357Amoxicillin Trihydrate Capsules, 250 mg and 500 mg.Public Health Service, HAS Supply Service Center.
62-359Bacitracin Topical Ointment, 500 units/gram.NMC Laboratories, Inc., 70-36 83d St., Glendale, NY 11385.
62-361Bacitracin-Neomycin-Polymyxin B Sulfate.Do.
62-528Amoxicillin Capsules USP, 250 mg and 500 mg.Laboratories Atral, S.A., c/o Louie F. Turner, P.O. Box 331044, Fort Worth, TX 76133-2924.
62-538Doxycycline Hyclate Tablets USP, 100 mg.Vintage Pharmaceuticals, Inc., 3241 Woodpark Blvd., Charlotte, NC 28206.
71-278PEG 3350 and Electrolytes for Oral Solution USP.E-Z-EM, Inc., 717 Main St., Westbury, NY 11590.
71-320PEG 3350 and Electrolytes for Oral Solution USP.DynaPharm, Inc., P.O. Box 2141, Del Mar, CA 92014.
71-419Chlorhexidine Gluconate Topical Solution 4%.Hygenics Pharmaceuticals, Inc., 26941 Cabot Rd., suite 128, Laguna Hills, CA 92653.
71-639Ibuprofen Tablets USP, 200 mg.Vintage Pharmaceuticals, Inc.
71-644Ibuprofen Tablets USP, 400 mg.Do.
71-777Clorazepate Dipotassium Capsules, 3.75 mg.Able Laboratories, 333 Cassell Dr., suite 3500, Baltimore, MD 21224.
71-778Clorazepate Dipotassium Capsules, 7.5 mg.Do.
71-779Clorazepate Dipotassium Capsules, 15 mg.Do.
72-319Glycoprep (PEG 3350 and Electrolytes for Oral Solution).Goldline Laboratories, 1900 West Commerical Blvd., Ft. Lauderdale, FL 33309.
72-399Sulfamethoxazole and Trimethorprim Oral Suspension USP.NASKA Pharmacal Co., Inc., P.O. Box 898 Riverview Rd., Lincolnton, NC 28093.
72-409Nifedipine Capsules USP, 10 mg.Chase Laboratories, Inc., 280 Chestnut St., Newark, NJ 07105.
73-421Nifedipine Capsules USP, 20 mg.Do.
74-080Carbidopa and Levodopa Tablets USP, 10 mg/100 mg, 25 mg/100 mg, and 25 mg/250 mg.SCS Pharmaceuticals, 4901 Searle Pkwy., Skokie, IL 60077.
80-094Triple Sulfoid Tablets.Pal-Pak, Inc., 1201 Liberty St., Allentown, PA 18102.
80-117Nitrofurantoin Tablets, 50 mg.Rachelle Laboratories, Inc., 700 Henry Ford Ave., P.O. Box 2029, Long Beach, CA 90801.
80-118Nitrofurantoin Tablets, 100 mg.Do.
80-335Prednisolone Tablets, 5 mg.Central Pharmaceutical, Inc., 110-128 East Third St., Seymour, IN 47274.
80-375Lidocaine HCl Injection USP, 2%.Rachelle Laboratories, Inc.
80-376Lidocaine HCl Injection USP, 1%.Do.
80-481Hydrocortisone Ointment USP.C & M Pharmacal, Inc., 1721 Maple Lane, Hazel Park, MI 48030-1215.
80-482Hydrocortisone Cream USP.Do.
80-562Prednisolone Tablets, 2.5 mg and 5 mg.John J. Ferrante.
80-568Hydrocortisone Tablets, 10 mg and 20 mg.Do.
80-967Vitamin A Capsules USP.West-Ward, Inc., 465 Industrial Lane, Eatontown, NJ 07724.
81-008Chlorzoxazone Tablets USP, 500 mg.Ferndale Laboratories, Inc., 780 West Eight Mile Rd., Ferndale, MI 48220.
83-102Vitamin D Capsules, 50,000 units.West-Ward, Inc.
83-156Hydrocortisone Acetate Cream, 1.0%.Parke-Davis, Div. of Warner-Lambert Co., 201 Tabor Rd., Morris Plains, NJ 07950.
83-161Dexamethasone Sodium Phosphate Injection.Dell Laboratories, Inc., 668 Front St., Teaneck, NJ 07666.
83-358Prednisolone Sodium Phosphate Ophthalmic Solution USP.Akorn, Inc.
83-400Propoxyphene HCl Capsules USP, 65 mg.Rachelle Laboratories, Inc.
83-643Acetaminophen and Codeine Phosphate Tablets, 325 mg/30 mg.Carnrick Laboratories, Inc., 65 Horse Hill Rd., Cedar Knolls, NJ 07927.
83-682Phendimetrazine Tartrate Tablets USP, 35 mg (yellow).Zenith Laboratories, Inc., 140 Legrand Ave., Northvale, NJ 07647.
83-787Chlorpheniramine Maleate Tablets, 4 mg.West-Ward, Inc.
Start Printed Page 16399
83-790Phendimetrazine Tartrate Tablets USP, 35 mg.Numark Laboratories, Inc., 75 Mayfield Ave., Edison, NJ 08837.
83-791Nitrofurazone Powder.Roberts Laboratories, Inc., 4 Industrial Way West, Eatontown, NJ 07724.
83-829Chlorpromazine HCl Tablets USP.Rachelle Laboratories, Inc.
83-977Selenium Sulfide.USV Pharmaceutical Corp., One Scarsdale Rd., Tuckahoe, NY 10707.
84-030Meprobamate Tablets, 400 mgFerndale Laboratories, Inc.
84-185Bethanechol Chloride Tablets, 10 mg.Wendt Laboratories, Inc., 100 Nancy Dr., P.O. Box 128, Belle Plaine, MN 56011.
84-186Bethanechol Chloride Tablets, 25 mg.Do.
84-255Sulfasalazine Tablets, 500 mg.William H. Rorer, Inc., 500 Virginia Dr., Fort Washington, PA 19034.
84-337Sulfisoxasole Tablets, 500 mg.Rachelle Laboratories, Inc.
84-377Prednisone Capsules, 50 mg.R. P. Scherer Corp., 2725 Scherer Dr., St. Petersburg, FL 33702.
84-492Prednisolone Acetate Injection.Akorn, Inc.
84-563Aminophylline Tablets, 200 mg.ICN Pharmaceuticals, Inc., 5040 Lester Rd., Cincinnati, OH 45213.
84-639Chlordiazepoxide HCl Capsules USP, 10 mg.Rachelle Laboratories, Inc.
84-727Lidocaine HCl Injection 2%.Pharmaton, Inc., 150 East 58th St., New York, NY 19155.
84-728Lidocaine HCl Injection, 2% with Epinephrine 1:50,000.Pharmaton, Inc., c/o Bass, Ullman & Lustrigman, 747 Third Ave., New York, NY 10017.
84-855Dexamethasone Sodium Phosphate Ophthalmic Solution USP, 0.1%.Akorn, Inc.
85-039Folic Acid Tablets USP, 1 mg.Wendt Laboratories, Inc.
85-040Isoniazed Tablets USP, 100 mg.Do.
85-041Meclizine HCl Tablets, 25 mg.Do.
85-042Methocarbamol Tablets USP, 500 mg.Do.
85-044Reserpine Tablets USP, 0.25 mg.Do.
85-086Chlordiazepoxide HCl Capsules, 5 mg.Rachelle Laboratories, Inc.
85-087Chlordiazepoxide HCl Capsules USP, 25 mg.Do.
85-091Isoniazid Tablets USP, 100 mg.Pharmavite Corp., 15451 San Fernando Mission Blvd., P.O. Box 9606, Mission Hills, CA 91346-9606.
85-104Chlorpheniramine Maleate Tablets USP, 4 mg.Do.
85-118Chlordiazepoxide HCl Capsules, 5 mg.John J. Ferrante.
85-119Chlordiazepoxide HCl Capsules, 10 mg.Do.
85-120Chlordiazepoxide HCl Capsules, 25 mg.Do.
85-341Butabartital Sodium Tablets USP, 30 mg.Vale Chemical Co., Inc., 1201 Liberty St., Allentown, PA 18102.
85-345Butabartital Sodium Tablets USP, 15 mg.Do.
85-477Secobarbital Sodium Capsules, 100 mg.ICN Pharmaceuticals, Inc., 222 North Vincent Ave., Covina, CA 91722.
85-509Diphenoxylate HCl and Atropine Sulfate Tablets USP, 2.5 mg/0.025 mg.Inwood Laboratories, Inc., Subsidiary of Forest Labs, Inc., 150 East 58th St., New York, NY 10155.
85-539Triamcinolone Acetonide Cream USP, 0.1%, 0.5%, and 0.025%.Zenith Goldline Pharmaceuticals, Inc.,
85-630Trichlormethiazide Tablets, 4 mg.Lannett Co., Inc., 9000 State Rd., Philadelphia, PA 19136.
85-733Hydrocortisone Cream USP, 1%.Zenith Goldine Pharmaceuticals, Inc.
85-777Selenium Sulfide USP.Do.
85-851Imipramine HCl Tablets USP, 25 mg.A. H. Robins Co., 1407 Cummings Dr., P.O. Box 26609, Richmond, VA 23261-6609.
86-116Phendimetrazine Tartrate Tablets, 17.5 mg.Camall Co., P.O. Box 218, Washington, MI 48094.
86-129Heparin Sodium Injection USP, 1,000 units/mL.Pharma-Serve, Inc., 218-20 98th Ave., Queens Village, NY 11429.
86-543Diphenhydramine HCl Capsules, 25 mg.Newtron Pharmaceuticals, Inc., 155 Knickerbocker Ave., Bohemia, NY 11716.
86-544Diphenhydramine HCl Capsules, 50 mg.Do.
86-766Nitrofurazone Ointment 0.2%.Wendt Laboratories, Inc.
87-081Nitrofurazone Solution 0.2%.Do.
87-328Trifluoperazine HCl Tablets USP, 5 mg.Zenith Goldline Pharmaceuticals, Inc.
87-375Triamcinolone Acetonide Ointment USP, 0.025%.Do.
87-376Triamcinolone Acetonide Ointment USP, 0.5%.Do.
87-377Triamcinolone Acetonide Ointment USP, 0.1%.Do.
87-427Hydrocortisone Cream USP, 1%.Do.
87-428Triamcinolone Acetonide Cream USP, 0.5%.Do.
87-429Triamcinolone Acetonide Cream USP, 0.1%.Do.
87-430Triamcinolone Acetonide Cream USP, 0.025%.Do.
87-489Hydrocortisone Lotion USP, 1%.Heran Pharmaceutical, Inc., 7215 Eckhert Rd., San Antonio, TX 78238.
87-612Trifluoperazine HCl Tablets USP, 1 mg.Zenith Goldline Pharmaceuticals, Inc.
87-613Trifluoperazine HCl Tablets USP, 2 mg.Do.
87-614Trifluoperazine HCl Tablets USP, 10 mg.Do.
Start Printed Page 16400
87-628Butalbital, Acetaminophen, and Caffeine Capsules, 50 mg/325 mg/40 mg.Roberts/Hauck Pharmaceuticals, Inc., Six Industrial Way West, Eatontown, NJ 07724.
87-818Sulfacetamide Sodium Ophthalmic Solution, 10%.Bausch & Lomb Pharmaceuticals, 8500 Hidden River Pkwy., Tampa, FL 33637.
87-834Hydrocortisone USP (micronized powder).Torch Laboratories, Inc., P.O. Box 248, Reisterstown, MD 21136.
87-865Chlorpromazine HCl Tablets, 25 mg.West-Ward, Inc.
88-024Phendimetrazine Tartrate Extended-Release Capsules, 105 mg.Numark Laboratories, Inc., 75 Mayfield Ave., Edison, NJ 08837.
88-059Sulfacetamide Sodium and Prednisolone Acetate Ophthalmic Suspension USP, 10%/0.5%.Akorn, Inc.
88-089Sulfacetamide Sodium and Prednisolone Acetate Ophthalmic Suspension USP, 10%/0.5%.Bausch & Lomb Pharmaceuticals.
88-189Reserpine and Hydrochlorthiazide Tablets USP, 0.125 mg/50 mg.West-Ward, Inc.
88-255Theophylline Sustained-Release Capsules, 300 mg.R. P. Scherer North America, P.O. Box 5600, Clearwater, FL 33518.
88-393Hydroxyzine Pamoate Capsules, 50 mg.Vanguard Labs, Packaging Div. of MWM Corp., 101-107 Samson St., P.O. Box K, Glasgow, KY 42141.
88-447Tropicamide Ophthalmic Solution USP, 1%.Akorn, Inc.
88-474Triprolidine HCl and Pseudoephedrine HCl, 1.25 mg/5 mL and 30 mg/5 mL.Newtron Pharmaceuticals, Inc.
89-268Butalbital and Acetaminophen Capsules, 50 mg/325 mg.Dunhall Pharmaceuticals, Inc., P.O. Box 100, Gravette, AR 72736.
89-273Hydrocortisone Cream USP, 1.0%.Topiderm, Inc., 155 Knickerbocker Ave., Bohemia, NY 11716.
89-274Triamcinolone Acetonide Cream USP, 0.025%.Do.
89-275Triamcinolone Acetonide Cream USP, 0.1%.Do.
89-276Triamcinolone Acetonide Cream USP, 0.5%.Do.
89-495Hydrocortisone Lotion USP, 1%.Beta Dermaceuticals, Inc., 5419 Bandera Rd., suite 708, San Antonio, TX 78238.
89-805Acetaminophen and Codeine Phosphate Tablets USP, 300 mg/30 mg.Vintage Pharmaceuticals, Inc.
89-828Acetaminophen and Codeine Phosphate Tablets USP, 300 mg/60 mg.Do.
89-990Acetaminophen and Codeine Phosphate Tablets USP, 300 mg/15 mg.Do.

Therefore, notice is given to the holders of the applications listed in the table and to all other interested persons that the Director of the Center for Drug Evaluation and Research proposes to issue an order under section 505(e) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(e)) withdrawing approval of the applications and all amendments and supplements thereto on the ground that the applicants have failed to submit reports required under § 314.81.

In accordance with section 505 of the act and 21 CFR part 314, the applicants are hereby provided an opportunity for a hearing to show why the applications listed previously should not be withdrawn and an opportunity to raise, for administrative determination, all issues relating to the legal status of the drug products covered by these applications.

An applicant who decides to seek a hearing shall file: (1) On or before April 27, 2000, a written notice of participation and request for a hearing, and (2) on or before May 30, 2000, the data, information, and analyses relied on to demonstrate that there is a genuine and substantial issue of fact that requires a hearing. Any other interested person may also submit comments on this notice. The procedures and requirements governing this notice of opportunity for a hearing, notice of participation and request for a hearing, information and analyses to justify a hearing, other comments, and a grant or denial of a hearing are contained in § 314.200 and in 21 CFR part 12.

The failure of an applicant to file a timely written notice of participation and request for a hearing, as required by § 314.200, constitutes an election by that applicant not to avail itself of the opportunity for a hearing concerning the proposal to withdraw approval of the applications and constitutes a waiver of any contentions concerning the legal status of the drug products. FDA will then withdraw approval of the applications and the drug products may not thereafter lawfully be marketed, and FDA will begin appropriate regulatory action to remove the products from the market. Any new drug product marketed without an approved new drug application is subject to regulatory action at any time.

A request for a hearing may not rest upon mere allegations or denials, but must present specific facts showing that there is a genuine and substantial issue of fact that requires a hearing. Reports submitted to remedy the deficiencies must be complete in all respects in accordance with § 314.81. If the submission is not complete or if a request for a hearing is not made in the required format or with the required reports, the Commissioner of Food and Drugs will enter summary judgment against the person who requests the hearing, making findings and conclusions, and denying a hearing.

All submissions under this notice of opportunity for a hearing must be filed in four copies. Except for data and information prohibited from public disclosure under section 301 of the act (21 U.S.C. 331(j)) or 18 U.S.C. 1905, the submissions may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 505 (21 U.S.C. 355)) and under authority delegated to the Director, Start Printed Page 16401Center for Drug Evaluation and Research (21 CFR 5.82).

Start Signature

Dated: March 13, 2000.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

End Signature End Supplemental Information

[FR Doc. 00-7589 Filed 3-27-00; 8:45 am]